Compass Therapeutics (NASDAQ:CMPX – Get Free Report) and BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.
Profitability
This table compares Compass Therapeutics and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compass Therapeutics | N/A | -38.71% | -34.72% |
| BioCryst Pharmaceuticals | -40.90% | -86.89% | 66.37% |
Earnings and Valuation
This table compares Compass Therapeutics and BioCryst Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Compass Therapeutics | $850,000.00 | 182.21 | -$66.49 million | ($0.40) | -2.15 |
| BioCryst Pharmaceuticals | $874.84 million | 2.28 | $263.86 million | ($1.50) | -5.19 |
BioCryst Pharmaceuticals has higher revenue and earnings than Compass Therapeutics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Compass Therapeutics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Compass Therapeutics and BioCryst Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compass Therapeutics | 1 | 3 | 12 | 1 | 2.76 |
| BioCryst Pharmaceuticals | 1 | 4 | 6 | 0 | 2.45 |
Compass Therapeutics presently has a consensus price target of $10.25, suggesting a potential upside of 1,091.86%. BioCryst Pharmaceuticals has a consensus price target of $19.44, suggesting a potential upside of 149.61%. Given Compass Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Compass Therapeutics is more favorable than BioCryst Pharmaceuticals.
Summary
Compass Therapeutics beats BioCryst Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
